Sotera Health (NASDAQ:SHC) Given New $17.00 Price Target at Barclays

Sotera Health (NASDAQ:SHC) had its price target lowered by investment analysts at Barclays from $18.00 to $17.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 24.72% from the stock’s previous close.

A number of other research analysts have also weighed in on the company. Royal Bank of Canada restated an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a report on Thursday, November 21st. Citigroup raised their price objective on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group started coverage on shares of Sotera Health in a research note on Friday, December 6th. They issued a “neutral” rating and a $14.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.08.

Sotera Health Price Performance

Shares of NASDAQ SHC opened at $13.63 on Tuesday. The stock has a market cap of $3.86 billion, a price-to-earnings ratio of 54.52 and a beta of 1.91. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.44. The firm’s 50-day simple moving average is $13.44 and its 200 day simple moving average is $14.57.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SHC. Blue Trust Inc. raised its holdings in shares of Sotera Health by 164.3% in the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock worth $25,000 after purchasing an additional 1,140 shares during the period. True Wealth Design LLC bought a new stake in shares of Sotera Health in the third quarter valued at $32,000. Quarry LP purchased a new position in shares of Sotera Health during the 4th quarter valued at $28,000. GAMMA Investing LLC grew its stake in shares of Sotera Health by 37.5% during the 4th quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock worth $56,000 after acquiring an additional 1,121 shares during the period. Finally, Capital Performance Advisors LLP purchased a new stake in Sotera Health in the 3rd quarter worth about $91,000. 91.03% of the stock is currently owned by hedge funds and other institutional investors.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.